Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ObjectivesThe aim of the study was to compare health-related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV-1 infection (PHI).MethodsA multicentre prospective cohort study of PHI patients, with an embedded randomized trial, was carried out. HRQL was assessed with the Medical Outcomes Study Health Survey for HIV (MOS-HIV) and a symptom checklist administered at weeks 0, 8, 24, 36, 48, 60, 72, 84 and 96. Mixed linear models were used for the analysis of differences in HRQL among the three groups.ResultsA total of 112 patients were included in the study: 28 received no treatment, 45 received 24 weeks of cART and 39 received 60 weeks of cART. Over 96 weeks of follow-up, the groups receiving 24 and 60 weeks of cART had better cognitive functioning than the no-treatment group (P = 0.005). Patients receiving 60 weeks of cART had less pain (P = 0.004), better role functioning (P = 0.001), better physical functioning (P = 0.02) and a better physical health summary score (P = 0.006) than the groups receiving no treatment or 24 weeks of cART. Mental health was better in patients receiving 24 weeks of cART than in patients in the no-treatment group or the group receiving 60 weeks of cART (P = 0.02). At week 8, patients in the groups receiving 24 and 60 weeks of cART reported more nausea (P = 0.002), diarrhoea (P ConclusionsTemporary cART during PHI had a significant positive impact on patients' HRQL as compared with no treatment, despite the initial, short-term occurrence of more physical symptoms, probably related to drug toxicity.

Original publication

DOI

10.1111/j.1468-1293.2012.01020.x

Type

Journal

HIV medicine

Publication Date

11/2012

Volume

13

Pages

630 - 635

Addresses

Division of Infectious Diseases, Department of Internal Medicine, Center for Infection and Immunity, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. m.l.grijsen@mc.uva.nl

Keywords

Primo-SHM study group, Humans, HIV-1, HIV Seropositivity, Disease Progression, Anti-HIV Agents, Viral Load, Drug Administration Schedule, Linear Models, Cohort Studies, Prospective Studies, Health Status, Time Factors, Quality of Life, Adolescent, Adult, Middle Aged, Female, Male, Young Adult, Surveys and Questionnaires